VLS Valneva SE

Declaration of shares and voting rights - Valneva SE - June 30, 2024

Declaration of shares and voting rights - Valneva SE - June 30, 2024

VALNEVA

Declaration of shares and voting rights

June 30, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: July 4, 2024

Number of shares

composing the share capital of Valneva 		Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 



139,276,901



ordinary shares with a par value of €0.15 each 		157,644,580 Transfer into bearer form of 750,000 shares with double voting rights



 



 Double voting rights granted on 7,015 ordinary shares 		Between June 1 &

June 30, 2024 		157,520,258

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
04/07/2024

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024

Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024 VALNEVA Déclaration d’actions et de droits de vote 30 juin 2024__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 4 juillet 2024 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droits de v...

July 4, 2024 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Declaration of shares and voting rights - Valneva SE - June 30, 2024

Declaration of shares and voting rights - Valneva SE - June 30, 2024 VALNEVA Declaration of shares and voting rights June 30, 2024__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: July 4, 2024 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* ...

July 4, 2024 1 EN
Team Pharma
  • Team Pharma
OSE OSE Immunothera...
EVT EVOTEC SE ... (+15)

ODDO : The macroeconomic environment is not helping the sector

The last few weeks had seen renewed interest in the sector, with stronger volumes, M&A activity and market transactions. Unfortunately, the political context in France has again undermined French biotechs. A large number of clinical results are expected in the next few months (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax, etc.). If successful, these could reinvigorate the sector. In the meantime, we are taking a more decisive stance, increasing the beta of the firms in our sa...

OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
07/03/24 July 3, 2024 1 EN
Team Pharma
  • Team Pharma
OSE OSE Immunothera...
EVT EVOTEC SE ... (+15)

ODDO : L'environnement macro ne favorise pas le secteur

Ces dernières semaines avaient laissé entrevoir un regain d’intérêt pour le secteur avec une hausse des volumes, du M&A et des opérations de marché. Malheureusement le contexte politique français vient à nouveau de pénaliser les biotechs françaises. Un nombre important de résultats cliniques sont attendus dans ces prochains mois (Ose, Aelis, Genfit, Medincell, Trangsene, Abivax…) qui pourraient, en cas de succès, redynamiser le secteur. Dans l’intervalle, nous décidons d’être plu...

OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
07/03/24 July 3, 2024 1 FR
Healthcare Team
  • Healthcare Team
EVT EVOTEC SE
DBV DBV Technologie... ... (+11)

Transfer of coverage

From 1st July, Bruno Bulic will be in charge of the following stocks:BasileaAbivaxAchillesDBVEvotecGeneuroGenfitInnate pharmaInventivaValerioValneva

EVT EVOTEC SE
DBV DBV TECHNOLOGIES SA
BSLN BASILEA PHARMACEUTICA AG
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
GNRO GENEURO SA
IVA INVENTIVA ADS
ACHL ACHILLES THERAPEUTICS PLC
ABVX ABIVAX
ALONX VALERIO THEARPEUTICS
07/01/24 July 1, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch